Has Fazleomar Mahmood, MD received payments from drug or device companies?

Yes. Drug and device makers reported $167,027 in general payments to Fazleomar Mahmood, MD across 185 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fazleomar Mahmood, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fazleomar Mahmood, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fazleomar Mahmood, MD

Rheumatology · Chelsea, MINPI 1275585200

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $139,950 of the $167,027 with a category attached, or 83.8%. 3 manufacturers reported payments, led by GSK at 56.7% of the total. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$167,027in general payments, 2019–2025

Across 185 payments — averaging $902.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$95K
AbbVie$72K
Amgen$26

What the payments were for

Consulting fees$7,1504%
Speaking & faculty fees$139,95084%
Travel & lodging$15,5679%
Food & beverage$4,3603%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	71	$94,678
AbbVie	113	$72,322
Amgen	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$54,246
BENLYSTA$50,625
NUCALA$42,828
Skyrizi$6,225
Humira$351

How this compares

$167,027 in reported general payments places this provider in the 95th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan →

Medicare billing

Part B allowed, 2024

$46,273

Medicare patients

188

Services billed

601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	193	$1,394,403
Humira(Cf) PenAdalimumab	159	$1,137,805
Humira PenAdalimumab	68	$484,275
RinvoqUpadacitinib	64	$437,608
Orencia ClickjectAbatacept	36	$194,490
Actemra ActpenTocilizumab	35	$140,428
OtezlaApremilast	29	$120,865
SimponiGolimumab	13	$78,756
MethotrexateMethotrexate Sodium	422	$20,440
Hadlima(Cf) PushtouchAdalimumab-Bwwd	13	$12,931
RasuvoMethotrexate/Pf	20	$10,735
Hydroxychloroquine Sulfate	159	$9,609
Leflunomide	91	$8,889
Prednisone	595	$5,961
Allopurinol	90	$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRinvoq	$72,322	$437,60864 claims
AmgenOtezla	$26	$120,86529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Chelsea

Amar MajjhooSaint Clair Shores$1.8M
Andrew SulichSaint Clair Shores$1.7M
Dinesh KhannaAnn Arbor$1.2M
Roman CzubatyjRochester Hills$764K
Delfin SantosRochester$242K
Allan MortonWarren$229K
Elena SchiopuAnn Arbor$180K
Alireza MeysamiNovi$170K
Barakat ThabetGrand Rapids$128K
Monika MohanOkemos$127K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →